Galectin Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying

7/24/24 7:03:14 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Investment Managers

Finance

Get the next $GALT alert in real time by email

The Dow Jones index closed lower by over 50 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform.

Bespoke Extracts

The Trade: Bespoke Extracts, Inc. (OTC:BSPK) CEO Michael Feinsod bought a total of 3,000 shares at an average price of $0.07. To acquire these shares, it cost around $210.
What's Happening: The company's stock jumped around 51% over the past six months.
What Bespoke Extracts Does: Bespoke Extracts Inc is focused on selling its proprietary line of specially-formulated, premium quality, hemp-derived CBD products.

Galectin Therapeutics

The Trade: Galectin Therapeutics Inc. (NASDAQ:GALT) Director Kary Eldred acquired a total of 400 shares at an average price of $2.39. To acquire these shares, it cost around $956.00.
What's Happening: On May 15, Galectin Therapeutics posted a wider-than-expected quarterly loss.
What Galectin Therapeutics Does: Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company.

RENN Fund

The Trade: RENN Fund, Inc. (NYSE:RCG) President and CEO Murray Stahl acquired a total of 1,499 shares at an average price of $1.81. The insider spent around $2,713 to buy those shares.
What's Happening: RENN Fund shares rose around 7% over the past month.
What RENN Fund Does: RENN Fund Inc is active in the financial services domain.

Read Next:

Best Buy, Kroger And 2 Other Stocks Insiders Are Selling

Get the next $GALT alert in real time by email

Crush Q1 2026 with the Best AI Superconnector

Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

AI-Powered Inbox

Context-aware email replies

Strategic Decision Support

Get Started with Standout.work

Recent Analyst Ratings for
$GALT
$RCG

Company	Date	Price Target	Rating	Analyst
Galectin Therapeutics Inc. $GALT	6/17/2025	$6.00	Buy	H.C. Wainwright

More analyst ratings

$GALT
$RCG
Press Releases

Fastest customizable press release news feed in the world

Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March 2027

NORCROSS, Ga., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension, today announced that the U.S. Food and Drug Administration (FDA) has provided a written response, and subsequent communications, to the Company's previously submitted Type C meeting request regarding the development program for belapectin, its investigational galectin-3 inhibitor. The FDA converted the Company's initial request for an in-person or teleconference meeting to a written response. Based on FDA's written feedback, the Company believes there is alignment with the Agency on th

12/19/25 8:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update

NORCROSS, Ga., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three and nine months ended September 30, 2025. "The new NAVIGATE data presented at AASLD further strengthen the clinical and mechanistic profile of belapectin. We continue to see encouraging consistency across key biomarkers—including FibroScan®, ELF, and PRO-C3—all supporting belapectin's durable antifibrotic activity and potential to slow disease progression in patients with compensated MASH cirrhosis. We submitted the NAVIGATE data package to the FDA and r

11/14/25 8:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Galectin Therapeutics Presented NAVIGATE Trial Results at the American Association for the Study of Liver Diseases (AASLD) 2025 Annual Meeting

New biomarker analyses from the NAVIGATE trial demonstrated consistent antifibrotic effects of belapectin 2 mg/kgUsing established criteria for clinically meaningful worsening, a lower proportion of patients treated with belapectin 2 mg/kg experienced ≥30% or ≥5 kPa increases in liver stiffness (LSM) by FibroScan® compared with placebo, indicating slowing of fibrosis progression and stabilization of liver functionAcross all ELF fibrosis risk categories, belapectin 2 mg/kg showed a lower incidence of new varices compared with placebo, with the largest benefit in patients with ELF > 11.3 (22.7% vs 42.9%), representing those at highest risk for liver complicationsPro-C3 biomarker analysis demon

11/10/25 8:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

$GALT
$RCG
Financials

Live finance-specific insights

Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update

NORCROSS, Ga., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three and nine months ended September 30, 2025. "The new NAVIGATE data presented at AASLD further strengthen the clinical and mechanistic profile of belapectin. We continue to see encouraging consistency across key biomarkers—including FibroScan®, ELF, and PRO-C3—all supporting belapectin's durable antifibrotic activity and potential to slow disease progression in patients with compensated MASH cirrhosis. We submitted the NAVIGATE data package to the FDA and r

11/14/25 8:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2025 and Provides Business Update

NORCROSS, Ga., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three and six months ended June 30, 2025. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, stated "We are encouraged by the continued analysis of data from our NAVIGATE trial , which further supports the clinical profile of belapectin in patients with MASH cirrhosis. At the European Association for the Study of the Liver (EASL) in May, we presented a clinically significant response in Fibroscan® (a key biomarker in MASH) and additi

8/14/25 8:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2025 and Provides Business Update

NORCROSS, Ga., May 15, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended March 31, 2025. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, stated "This quarter, we remained laser-focused on advancing additional analyses for belapectin. I was extremely encouraged by the feedback we received last week at the European Association for the Study of the Liver (EASL), specifically that we successfully demonstrated a clinically significant response in a key biomarker (Fibroscan®) that is used to

5/15/25 8:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

$GALT
$RCG
Leadership Updates

Live Leadership Updates

Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going

USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 18, 2025 /PRNewswire/ -- USA News Group News Commentary – According to a recent report in Newsweek, more Americans younger than 50 are getting cancer. In fact, the report cites a recent study from the National Institutes of Health (NIH), which found that between 2010 and 2019, more than 2 million Americans aged 15 to 49 were diagnosed with cancer, with early-onset cases rising significantly in 14 different cancer types, including breast, colorectal, and kidney cancers. The dire statistics from the study come at a time where Bloomberg has recently reported on the skyrocketing costs of cancer drugs,

6/18/25 11:19:00 AM ET

Medical/Dental Instruments

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Biotechnology: Pharmaceutical Preparations

Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Officer

NORCROSS, Ga., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced the appointment of Khurram Jamil, M.D., an accomplished senior executive with expertise in liver disease to Chief Medical Officer effective immediately. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said "We are very excited to elevate Dr. Jamil to Chief Medical Officer. After joining us in March 2024 as Vice President Clinical Development and Medical Director, Khurram has quickly integrated himself into our team and has led the management of our NAVIGATE clinical trial of belapectin

8/1/24 8:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development

NORCROSS, Ga., March 12, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced the appointment of Khurram Jamil, M.D. as Vice President, Clinical Development. Dr. Jamil brings to Galectin almost two decades of experience in clinical development across the biotechnology industry. "We are pleased to welcome Khurram to the Galectin team at such a meaningful time of our development program" said Pol F. Boudes, M.D., Chief Medical Officer. "His breadth of expertise in clinical development, especially in hepatology and liver cirrhosis, along with his experience with regulatory interactions a

3/12/24 8:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care